Sign in

CIK 0001649989

  • Non-accelerated filer
  • Smaller reporting company

Outlook Therapeutics, Inc.

Sign in to watch
Ticker
OTLK
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Sep 30
Incorporated
DE
Entity type
Operating
EIN
383982704
Phone
+1 609-619-3990
Business address
111 S. WOOD AVENUE, UNIT #100, ISELIN, NJ, 08830
Former names
Oncobiologics, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2019-06-17 BioLexis Pte Ltd. Director Exercise or conversion +2,181,818 14,039,494
2019-06-17 BioLexis Pte Ltd. Director Exercise or conversion · Warrant (Right to Buy) −3,636,364 0
2019-04-12 BioLexis Pte Ltd. Director Grant or award +3,636,364 $2.75 $10.0M 11,857,676
2019-04-12 BioLexis Pte Ltd. Director Grant or award · Warrant (Right to Buy) +3,636,364 3,636,364
2019-04-12 BioLexis Pte Ltd. Director Grant or award · Warrant (Right to Buy) +3,636,364 3,636,364
2019-03-31 BioLexis Pte Ltd. Director Other acquisition · Series A-1 Convertible Preferred Stock +1,542 63,250
2019-02-01 BioLexis Pte Ltd. Director Grant or award +4,288,624 $0.93 $4.0M 65,770,503
2019-01-02 BioLexis Pte Ltd. Director Grant or award +4,288,624 $0.93 $4.0M 61,481,879
2018-12-31 BioLexis Pte Ltd. Director Other acquisition · Series A-1 Convertible Preferred Stock +1,505 61,708
2018-12-03 BioLexis Pte Ltd. Director Grant or award +4,288,624 $0.93 $4.0M 57,193,255
2018-11-07 BioLexis Pte Ltd. Director Grant or award +8,577,248 $0.93 $8.0M 52,904,631
2018-09-30 BioLexis Pte Ltd. Director Other acquisition · Series A-1 Convertible Preferred Stock +1,468 60,203
2018-09-30 BioLexis Pte Ltd. 10% owner Other acquisition · Series A-1 Convertible Preferred Stock +1,648 60,383

Page 2 of 2 · 33 trades